Luye Pharma Group Ltd.
West Part, Room 1107
Zhubang 2000 Business Center, No, 100
35 articles with Luye Pharma Group Ltd.
Luye Pharma Releases Top-Line Results from a Phase II Clinical Trial of Its New Antidepressant Ansofaxine Hydrochloride Extended-Release Tablets
Luye Pharma Group released the encouraging top-line results from a Phase II clinical trial of its new antidepressant, Ansofaxine Hydrochloride Extended-Release Tablets, at the 19th National Psychiatry Conference of the Chinese Medical Association.
Researchers in China are busy developing several treatments, combining vaccines and drugs for COVID-19, and also working on monoclonal antibodies treatment.
Boan Biotech to Present the Pre-clinical Data of Its Proprietary CD3+ T-cell Engager Platform and CEA/CD3 Bispecific Antibody at World Bispecific Summit
Boan Biotech, a subsidiary of Luye Pharma Group, will orally present the pre-clinical data of its proprietary CD3+ T-cell engager platform and CEA/CD3 bispecific antibody at World Bispecific Summit 2021.
Italfarmaco Group Enters Into an Agreement with Luye Pharma to Commercialize Alzheimer’s Disease Treatment Rivastigmine Multi-Day Transdermal Patch in Four European Countries
Italfarmaco Group adds innovative Alzheimer’s disease therapy to its neurology-based product portfolio
Luye Pharma Group Selects LifeSphere® Signal and Risk Management to Automate Drug Safety Signal Detection
ArisGlobal, the leading provider of life sciences software that automates core drug development functions for over 250 life sciences companies, announced Luye Pharma Group, an international pharmaceutical company dedicated to the R&D, manufacturing, and sale of innovative medications has selected LifeSphere® Signal and Risk Management as its next-generation signal detection tool.
Luye Pharma Group (02186.HK) reported its financial results for 2019 on March 27, 2020 . According to the results, the company has achieved a total revenue of RMB 6.358 billion , up 22.9% year-on-year. EBITDA was RMB 2.488 billion , up 26.9% year-on-year; and normalized profit attributed to shareholders was RMB 1.592 billion , up 19.4
Luye Pharma Group has announced that the U.S. Food and Drug Administration (FDA) has reviewed and accepted the filing of a New Drug Application (NDA) for LY03005, a new chemical drug for the treatment of major depressive disorder. LY03005 is the company's second drug in the central nervous system (CNS) therapeutic area currently in the U.S.
Luye Pharma Grants Cipla Medpro Exclusive Distribution and Marketing Rights for Seroquel® and Seroquel XR® in South Africa and Certain Neighbouring Countries
Luye Pharma Group has announced that it has entered into an exclusive distribution and marketing service agreement with Cipla Medpro South Africa Limited, for Seroquel® and Seroquel XR® in South Africa, Namibia and Botswana.
Developments in the Frontiers of Diagnosis and Treatment for Bipolar Disorder and Schizophrenia Receive Extensive Attention
Luye Pharma First Half of 2019 Results: Strong Revenue Growth and Substantial Development of R&D Product Pipelines
Luye Pharma Group released its financial results for the first half of 2019 on August 28.
Rykindo®, Luye Pharma's innovative, independently developed Extended-Release Microspheres formulation for injection, is one step closer to going on the U.S. market.
Luye Pharma's Rykindo® Expected to Be the First Chinese Innovative Drug to Receive U.S. FDA Approval
Luye Pharma Group has announced submission of a new drug application to the U.S. Food and Drug Administration for Rykindo®, completed on March 28.
Luye Pharma Reaches Strategic Partnership with AstraZeneca, Strengthens Commitment to Cardiovascular Therapeutic Field
Luye Pharma grants AstraZeneca exclusives rights to promote Xuezhikang Capsules in mainland China
Luye Pharma Announces Innovative Drug - Risperidone Extended Release Microspheres for Injection has Reached Final Stage of NDA Process
Luye Pharma Group today announced that it has entered the final stage of New Drug Application (NDA) submissions for the innovative drug, Risperidone Extended Release Microspheres for Injection ('LY03004), after previous positive pre-NDA meeting with the U.S. Food and Drug Administration (FDA) and subsequent related procedures.
Luye Pharma's Goserelin Acetate Extended-release Microspheres Start Phase III Clinical Trials in China, Paralleling Smooth Progress with U.S. Regulators
Luye Pharma announced that its independently developed drug, Goserelin Acetate Extended-release Microspheres for Injection (LY01005), has entered phase III clinical trials for prostate cancer in China.
Luye Pharma Releases its Financial Results for the First Half of 2018: Double-Digit Growth in Core Product Sales, Exceeded Expectations in Sales, R&D and M&As
Luye Pharma Group released its financial results for the first half of 2018 on August 26, with the financial report showing the company has maintained strong business performance and double-digit growth in the sale of its established products - significantly higher than the industry average.
Luye Pharma Well Positioned for CNS Market with the Approval of A New Indication for Seroquel XR in China
Luye Pharma Group has announced that its Central Nervous System (CNS) drug, Seroquel XR (Quetiapine Fumarate XR), has received approval from the official Chinese medical authorities for a new indication in the treatment of depression arising from bipolar disorder.
Luye Pharma Bolsters Its Global Analgesics Portfolio with China Class 1.1 New Compound LY03012 to Start Phase I Clinical Trials
Luye Pharma Group announced that clinical applications of the company's new compound candidate have been formally accepted by the China Food and Drug Administration.
The $538 million acquisition by Luye Pharma Group Ltd. (HKSE:2186) of Seroquel quetiapine fumarate from AstraZeneca plc (LSE:AZN; NYSE:AZN) will lay the commercial groundwork in new emerging markets for the Chinese pharma's internal CNS pipeline.
License agreement to jointly develop chimeric antigen receptor T-cell therapies and biologic drug candidates in immuno-oncology